N-Desalkyl flurazepam (BioDeep_00000018087)

   

human metabolite Endogenous blood metabolite Chemicals and Drugs


代谢物信息卡片


7-chloro-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one

化学式: C15H10ClFN2O (288.0465652)
中文名称: 7-氯-5-(2-氟苯基)-1,3-二氢-2H-1,4-苯并二氮杂卓-2-酮
谱图信息: 最多检出来源 Homo sapiens(blood) 5.13%

分子结构信息

SMILES: C1C(=O)NC2=C(C=C(C=C2)Cl)C(=N1)C3=CC=CC=C3F
InChI: InChI=1S/C15H10ClFN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)

描述信息

N-Desalkyl flurazepam is a metabolite of flurazepam. Flurazepam (marketed under the brand names Dalmane and Dalmadorm) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It produces a metabolite with a very long half-life (40–250 hours), which may stay in the bloodstream for up to four days. http://www. non-benzodiazepines. org. uk/equivalents. html Flurazepam is therefore unsuitable as a sleeping medication for some individuals due to next day sedation. (Wikipedia)

同义名列表

8 个代谢物同义名

7-chloro-5-(2-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one; 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one; N-Desalkyl-2-oxoquazepam; N-Desalkyl flurazepam; N-Desalkylflurazepam; Norflutoprazepam; Norfludiazepam; Norflurazepam



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Jing Zhou, Koji Yamaguchi, Youkichi Ohno. Quantitative analysis of quazepam and its metabolites in human blood, urine, and bile by liquid chromatography-tandem mass spectrometry. Forensic science international. 2014 Aug; 241(?):e5-12. doi: 10.1016/j.forsciint.2014.04.027. [PMID: 24856286]
  • Pi Cheng, Quan Zhang, Yun-Bao Ma, Zhi-Yong Jiang, Xue-Mei Zhang, Feng-Xue Zhang, Ji-Jun Chen. Synthesis and in vitro anti-hepatitis B virus activities of 4-aryl-6-chloro-quinolin-2-one and 5-aryl-7-chloro-1,4-benzodiazepine derivatives. Bioorganic & medicinal chemistry letters. 2008 Jul; 18(13):3787-9. doi: 10.1016/j.bmcl.2008.05.065. [PMID: 18524583]
  • Kimiyasu Kato, Norio Yasui-Furukori, Takashi Fukasawa, Toshiaki Aoshima, Akihito Suzuki, Muneaki Kanno, Koichi Otani. Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug. Therapeutic drug monitoring. 2003 Aug; 25(4):473-7. doi: 10.1097/00007691-200308000-00010. [PMID: 12883232]
  • J M Hilbert, D Battista. Quazepam and flurazepam: differential pharmacokinetic and pharmacodynamic characteristics. The Journal of clinical psychiatry. 1991 Sep; 52 Suppl(?):21-6. doi: . [PMID: 1680120]
  • K Schaffler, G Kauert, C H Wauschkuhn, W Klausnitzer. Longitudinal study on pharmacodynamics and pharmacokinetics of acute, steady-state and withdrawn quazepam. Arzneimittel-Forschung. 1989 Feb; 39(2):276-83. doi: . [PMID: 2567171]
  • S K Gupta, E H Ellinwood. Liquid chromatographic assay and pharmacokinetics of quazepam and its metabolites following sublingual administration of quazepam. Pharmaceutical research. 1988 Jun; 5(6):365-8. doi: 10.1023/a:1015907611170. [PMID: 3244647]
  • E J Fazackerley, N P Randall, B J Pleuvry, I Bradbrook, G E Mawer. The respiratory effects of oral ethyl loflazepate in volunteers. British journal of clinical pharmacology. 1987 Feb; 23(2):183-7. doi: 10.1111/j.1365-2125.1987.tb03027.x. [PMID: 2881572]
  • N Zampaglione, J M Hilbert, J Ning, M Chung, R Gural, S Symchowicz. Disposition and metabolic fate of 14C-quazepam in man. Drug metabolism and disposition: the biological fate of chemicals. 1985 Jan; 13(1):25-9. doi: . [PMID: 2858372]
  • J M Hilbert, R P Gural, S Symchowicz, N Zampaglione. Excretion of quazepam into human breast milk. Journal of clinical pharmacology. 1984 Oct; 24(10):457-62. doi: 10.1002/j.1552-4604.1984.tb01819.x. [PMID: 6150944]
  • J M Hilbert, M Chung, E Radwanski, R Gural, S Symchowicz, N Zampaglione. Quazepam kinetics in the elderly. Clinical pharmacology and therapeutics. 1984 Oct; 36(4):566-9. doi: 10.1038/clpt.1984.220. [PMID: 6478742]
  • J Hilbert, B Pramanik, S Symchowicz, N Zampaglione. The disposition and metabolism of a hypnotic benzodiazepine, quazepam, in the hamster and mouse. Drug metabolism and disposition: the biological fate of chemicals. 1984 Jul; 12(4):452-9. doi: NULL. [PMID: 6148212]
  • J M Hilbert, M Chung, G Maier, R Gural, S Symchowicz, N Zampaglione. Effect of sleep on quazepam kinetics. Clinical pharmacology and therapeutics. 1984 Jul; 36(1):99-104. doi: 10.1038/clpt.1984.146. [PMID: 6734056]
  • M Chung, J M Hilbert, R P Gural, E Radwanski, S Symchowicz, N Zampaglione. Multiple-dose quazepam kinetics. Clinical pharmacology and therapeutics. 1984 Apr; 35(4):520-4. doi: 10.1038/clpt.1984.70. [PMID: 6705450]